Log In


Company Name : Takeda Pharmaceutical Company Limited

Friday, February 17, 2017 9:00AM IST (3:30AM GMT)


Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.

– Significantly Enhances Takeda’s Global Oncology Portfolio –; – Accretive to FY2018 Underlying Core Earnings –; – Reinforces Takeda’s Commitment to Developing Medicines for Patients Living with Cancer –

Osaka, Japan & Cambridge, Mass., United States

Takeda Pharmaceutical Company Limited (TSE:4502) (“Takeda”) announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) (“ARIAD”) for $24.00 per share in cash.


“We are very pleased to have completed the acquisition of ARIAD Pharmaceuticals. The addition of ARIAD’s innovative targeted therapies and research and development capabilities strengthens and diversifies our oncology business, positioning Takeda for sustainable long-term growth in this priority therapeutic area,” said Christophe Weber, president and chief executive officer of Takeda. “We are particularly excited by the global potential of brigatinib, an investigational drug product, which we believe will become a best-in-class ALK inhibitor for non-small cell lung cancer with the potential to achieve peak annual sales of over $1 billion. We are also impressed with the swiftness and agility of Takeda and ARIAD employees as they have planned for a successful integration while remaining focused on strategic goals. This bodes very well for the future of our combined business, and we look forward to building on this strong start to maximize the benefit of Iclusig® (ponatinib) and potential of brigatinib for cancer patients.”


“The acquisition of ARIAD is transformational for Takeda Oncology. Iclusig enhances our strong position in hematology in the U.S., and brigatinib has the potential to broaden our solid tumor franchise globally,” said Christophe Bianchi, president of Takeda Oncology. “There is a strong cultural fit between our two companies, with a shared mission to advance innovative therapies to improve the lives of patients with cancer. We have been working together over the past month to plan for a smooth integration of our businesses and we will work closely with regulatory authorities on our brigatinib market authorization submissions.”


Takeda continues to expect the transaction to be accretive to Underlying Core Earnings by FY2018. Strong revenue growth and synergy savings will offset increased sales and marketing costs for the anticipated brigatinib launch.


Tender Offer Details


Takeda completed the acquisition through a tender offer and subsequent merger of ARIAD with Kiku Merger Co., Inc., a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. ARIAD is now an indirect wholly owned subsidiary of Takeda.


The tender offer for all of the outstanding shares of ARIAD common stock expired as scheduled, immediately following the offer’s expiration time of 11:59 p.m., Eastern Time, on February 15, 2017. Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has advised Takeda that 158,558,628 shares of ARIAD common stock were tendered, representing approximately 81.4% of the shares outstanding. All of the conditions to the tender offer having been satisfied, Takeda’s indirect wholly owned subsidiary Kiku Merger Co., Inc. has accepted for payment and will promptly pay for all shares tendered. The transaction will be funded by approximately $3.5 billion of new debt and the remainder from existing cash. Takeda is expected to remain investment grade and the transaction has no impact on Takeda’s dividend policy.


On February 16, 2017, Takeda completed its acquisition of ARIAD through the merger of Kiku Merger Co., Inc. with ARIAD without a vote of ARIAD’s shareholders pursuant to Section 251(h) if the Delaware General Corporation Law. As a result of the merger, ARIAD became an indirect wholly owned subsidiary of Takeda. In connection with the merger, all ARIAD shares not purchased in the tender offer have been converted into the right to receive $24.00 per share in cash, without interest (less any required withholding taxes), the same amount paid for all shares validly tendered and not validly withdrawn in the tender offer. ARIAD common stock will cease to be traded on the NASDAQ Global Select Market.


Evercore Partners acted as financial advisor and Cleary Gottlieb Steen & Hamilton LLP acted as legal advisor to Takeda. J.P. Morgan Securities LLC, Goldman, Sachs & Co. and Lazard acted as financial advisors and Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to ARIAD.


About Takeda Pharmaceutical Company


Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. Additional information about Takeda is available through its corporate website, www.Takeda.com.


Please see Iclusig® (ponatinib) full Prescribing Information, including Boxed Warning.


Cautionary Statement Regarding Forward-Looking Statements


This press release contains forward-looking statements. When used in this press release, the words “can,” “will,” “believes,” “intends,” “expects,” “is expected,” similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Such statements are based on a number of assumptions that could ultimately prove inaccurate, and are subject to a number of risks. Neither Takeda nor ARIAD assumes any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.



Click here for Media Contact Details
CONTACTS : Media and Investors Takeda Investors Noriko Higuchi, +81 (0) 3-3278-2306 noriko.higuchi@Takeda.com or Takeda Media outside Japan Shawn Goodman, +1-415-250-0766 shawn.goodman@Takeda.com or Japanese Media Tsuyoshi Tada, +81 (0) 3-3278-2417 tsuyoshi.tada@Takeda.com or Finsbury Kal Goldberg, +1-646-805-2005 kal.goldberg@finsbury.com or Chris Ryall, +1-646-805-2078 chris.ryall@finsbury.com

More News from Takeda Pharmaceutical Company Limited

11/04/2017 5:13PM

Takeda Enters into Strategic Collaboration with NuBiyota for Microbiome Therapeutics

Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced a strategic collaboration with NuBiyota LLC for the development of Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications with a ...

05/04/2017 8:25PM

Takeda Completes Enrollment of More Than 20,000 Children and Adolescents in Global Phase 3 Trial of Dengue Vaccine Candidate

Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that it has completed enrollment of 20,100 children and adolescents ages 4 through 16in its global, pivotal Phase 3 Tetravalent ...

30/03/2017 6:40PM

Takeda's Dengue Vaccine Candidate Elicited Broad Immune Responses in Children and Adolescents Living in Dengue-Endemic Areas; Interim Phase 2 Analysis Published in The Lancet Infectious Diseases

Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that data from a 6-month interim analysis* of the ongoing DEN-204 trial of its live-attenuated tetravalent dengue vaccine ...

Similar News

27/04/2017 9:45PM Document

Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; Board of Directors Recommends 2:1 Bonus Shares

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, announced today its consolidated financial results for the fourth quarter and full year FY17.

No Image

27/04/2017 7:20PM Image Youtube Script

Microfinance Organization Grameen Koota Receives ISC-FICCI 2017 Sanitation Award

Microfinance Organization Grameen Koota has received the ISC-FICCI 2017 Award for Best Financial Accessibility for Sanitation.